Kyntra Bio, Inc. (KYNB) - Net Assets
Based on the latest financial reports, Kyntra Bio, Inc. (KYNB) has net assets worth $-30.77 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($109.63 Million) and total liabilities ($140.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. For live market cap and overall valuation, see Kyntra Bio, Inc. (KYNB) total market value.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-30.77 Million |
| % of Total Assets | -28.07% |
| Annual Growth Rate | -22.46% |
| 5-Year Change | -98.05% |
| 10-Year Change | -97.44% |
| Growth Volatility | 89.92 |
Kyntra Bio, Inc. - Net Assets Trend (2012–2025)
This chart illustrates how Kyntra Bio, Inc.'s net assets have evolved over time, based on quarterly financial data.
Annual Net Assets for Kyntra Bio, Inc. (2012–2025)
The table below shows the annual net assets of Kyntra Bio, Inc. from 2012 to 2025. See KYNB equity to assets ratio to measure how much of total assets are equity-financed.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $4.47 Million | +102.44% |
| 2024-12-31 | $-183.63 Million | -13.22% |
| 2023-12-31 | $-162.20 Million | -10859.39% |
| 2022-12-31 | $-1.48 Million | -100.65% |
| 2021-12-31 | $229.11 Million | -48.10% |
| 2020-12-31 | $441.45 Million | -17.55% |
| 2019-12-31 | $535.41 Million | +1.31% |
| 2018-12-31 | $528.47 Million | -9.27% |
| 2017-12-31 | $582.45 Million | +232.62% |
| 2016-12-31 | $175.11 Million | -11.03% |
| 2015-12-31 | $196.82 Million | -18.22% |
| 2014-12-31 | $240.68 Million | +123.67% |
| 2013-12-31 | $107.60 Million | -11.93% |
| 2012-12-31 | $122.18 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kyntra Bio, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 145821100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $1.01 Million | % |
| Other Comprehensive Income | $-2.18 Million | % |
| Other Components | $1.68 Billion | % |
| Total Equity | $-30.04 Million | 100.00% |
Kyntra Bio, Inc. Competitors by Market Cap
The table below lists competitors of Kyntra Bio, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Franklin Wireless Corp
NASDAQ:FKWL
|
$28.75 Million |
|
Lyka Labs Limited
NSE:LYKALABS
|
$28.76 Million |
|
Kincora Copper Ltd
V:KCC
|
$28.76 Million |
|
Touch Ventures Ltd
AU:TVL
|
$28.77 Million |
|
Katapult Holdings Inc
NASDAQ:KPLT
|
$28.74 Million |
|
IDENTILLECT TECHN. O.N.
F:8ID
|
$28.74 Million |
|
Gencurix Inc
KQ:229000
|
$28.74 Million |
|
BayWa Aktiengesellschaft
F:BYW
|
$28.71 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kyntra Bio, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -225,601,999 to -30,038,000, a change of 195,563,999.
- Net income of 183,452,000 contributed positively to equity growth.
- Dividend payments of 3,947,000 reduced retained earnings.
- Share repurchases of 69,000 reduced equity.
- Other comprehensive income increased equity by 3,549,999.
- Other factors increased equity by 12,578,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $183.45 Million | +610.73% |
| Dividends Paid | $3.95 Million | -13.14% |
| Share Repurchases | $69.00K | -0.23% |
| Other Comprehensive Income | $3.55 Million | +11.82% |
| Other Changes | $12.58 Million | +41.87% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Kyntra Bio, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $179.33 | $8.11 | x |
| 2013-12-31 | $42.16 | $8.11 | x |
| 2014-12-31 | $96.37 | $8.11 | x |
| 2015-12-31 | $73.57 | $8.11 | x |
| 2016-12-31 | $62.09 | $8.11 | x |
| 2017-12-31 | $192.90 | $8.11 | x |
| 2018-12-31 | $151.44 | $8.11 | x |
| 2019-12-31 | $148.94 | $8.11 | x |
| 2020-12-31 | $117.46 | $8.11 | x |
| 2021-12-31 | $56.62 | $8.11 | x |
| 2022-12-31 | $-5.73 | $8.11 | x |
| 2023-12-31 | $-52.46 | $8.11 | x |
| 2024-12-31 | $-56.38 | $8.11 | x |
| 2025-12-31 | $-7.43 | $8.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kyntra Bio, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2848.63%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-28.98%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -34.47% | -49.40% | 0.25x | 2.81x | $-42.02 Million |
| 2013 | -18.74% | -14.63% | 0.34x | 3.72x | $-22.92 Million |
| 2014 | -26.88% | -43.24% | 0.28x | 2.18x | $-81.64 Million |
| 2015 | -48.31% | -47.44% | 0.38x | 2.65x | $-103.53 Million |
| 2016 | -39.58% | -34.35% | 0.38x | 3.01x | $-77.26 Million |
| 2017 | -22.41% | -100.43% | 0.14x | 1.60x | $-182.52 Million |
| 2018 | -16.97% | -40.58% | 0.24x | 1.73x | $-137.34 Million |
| 2019 | -14.91% | -30.00% | 0.30x | 1.66x | $-128.58 Million |
| 2020 | -44.84% | -107.36% | 0.21x | 1.96x | $-231.51 Million |
| 2021 | -138.67% | -123.25% | 0.30x | 3.70x | $-310.94 Million |
| 2022 | 0.00% | -208.66% | 0.23x | 0.00x | $-291.51 Million |
| 2023 | 0.00% | -607.29% | 0.11x | 0.00x | $-263.82 Million |
| 2024 | 0.00% | -160.63% | 0.14x | 0.00x | $-25.02 Million |
| 2025 | 0.00% | 2848.63% | 0.05x | 0.00x | $186.46 Million |
Industry Comparison
This section compares Kyntra Bio, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $216,846,716
- Average return on equity (ROE) among peers: -55.39%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kyntra Bio, Inc. (KYNB) | $-30.77 Million | -34.47% | N/A | $28.74 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $148.28 Million |
| Abcellera Biologics Inc (ABCL) | $1.15 Billion | -12.70% | 0.29x | $2.99 Billion |
| Abeona Therapeutics Inc (ABEO) | $15.00 Million | -36.18% | 1.03x | $335.61 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $-85.14 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.56 Billion |
| Arbutus Biopharma Corp (ABUS) | $35.44 Million | -26.32% | 0.18x | $906.70 Million |
| ABVC Biopharma Inc (ABVC) | $10.00K | -200.00% | 3.00x | $18.49 Million |
| Abivax SA American Depositary Shares (ABVX) | $18.59 Million | -164.77% | 1.78x | $10.16 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $699.13 Million | -33.65% | 0.12x | $5.07 Billion |
About Kyntra Bio, Inc.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible fact… Read more